Antisense Deal STATs Rising with Isis' Latest: AstraZeneca
By Randy Osborne
Wednesday, December 12, 2012
Isis Pharmaceuticals Inc.'s latest antisense deal this time with AstraZeneca plc, for $25 million and $6 million more possible next year, plus potential milestone payments afterward helps the company identify more targets and pay for Phase II work with a lymphoma compound, SIS-STAT3Rx, to which the new partner also bought a license.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.